Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.57 -1.7%	$21.97	$16.10 ▼ $41.94	$3.48B	0.73	2.31 million shs	1.55 million shs
BEAM Beam Therapeutics	$16.36 -2.9%	$18.72	$13.52 ▼ $35.25	$1.66B	2.14	2.39 million shs	1.90 million shs
BLUE bluebird bio	$4.97	$4.78	$3.20 ▼ $25.10	$48.67M	0.27	452,966 shs	N/A
CRSP CRISPR Therapeutics	$51.83 -2.3%	$55.74	$30.04 ▼ $71.13	$4.71B	1.81	2.53 million shs	1.59 million shs
LLY Eli Lilly and Company	$732.41 +0.1%	$748.68	$623.78 ▼ $969.65	$693.20B	0.47	6.78 million shs	2.55 million shs
PFE Pfizer	$24.74 +0.6%	$24.79	$20.92 ▼ $30.43	$140.65B	0.55	43.00 million shs	37.00 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	-1.43%	+20.13%	+44.04%	-29.13%
BEAM Beam Therapeutics	0.00%	-1.68%	-13.12%	+1.05%	-38.68%
BLUE bluebird bio	0.00%	0.00%	0.00%	+0.20%	-55.74%
CRSP CRISPR Therapeutics	0.00%	-4.58%	-7.59%	+40.27%	+8.61%
LLY Eli Lilly and Company	0.00%	+3.05%	-3.82%	-1.90%	-23.71%
PFE Pfizer	0.00%	-4.21%	+5.32%	+5.52%	-14.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	3.8658 of 5 stars	3.3	1.0	0.0	4.4	2.3	2.5	0.6
BEAM Beam Therapeutics	2.1971 of 5 stars	3.5	0.0	0.0	0.0	2.9	2.5	0.6
BLUE bluebird bio	1.6216 of 5 stars	3.1	0.0	0.0	0.0	0.6	1.7	1.3
CRSP CRISPR Therapeutics	3.5798 of 5 stars	4.2	3.0	0.0	0.0	2.3	3.3	0.6
LLY Eli Lilly and Company	5 of 5 stars	4.3	5.0	3.3	4.0	3.1	3.3	3.8
PFE Pfizer	4.7829 of 5 stars	2.2	3.0	4.2	4.5	2.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	23.75% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	196.18% Upside
BLUE bluebird bio	2.14	Hold	$25.75	418.11% Upside
CRSP CRISPR Therapeutics	2.47	Hold	$71.60	38.14% Upside
LLY Eli Lilly and Company	2.67	Moderate Buy	$950.17	29.73% Upside
PFE Pfizer	2.39	Hold	$28.12	13.66% Upside

Current Analyst Ratings Breakdown

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/26/2025	CRSP CRISPR Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$942.00 ➝ $875.00
8/11/2025	LLY Eli Lilly and Company	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,010.00 ➝ $900.00
8/8/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,050.00 ➝ $895.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.46	N/A	N/A	$1.84 per share	14.98
BEAM Beam Therapeutics	$60.27M	27.46	N/A	N/A	$8.86 per share	1.85
BLUE bluebird bio	$103.95M	0.47	N/A	N/A	$35.59 per share	0.14
CRSP CRISPR Therapeutics	$37.31M	126.35	N/A	N/A	$22.64 per share	2.29
LLY Eli Lilly and Company	$45.04B	15.39	$14.23 per share	51.47	$15.03 per share	48.73
PFE Pfizer	$63.63B	2.21	$4.36 per share	5.67	$15.62 per share	1.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
BLUE bluebird bio	-$211.91M	-$41.32	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	47.87	23.54	1.02	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.16	8.16	0.88	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	$0.90	5.50%	N/A	N/A	N/A
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.82%	N/A	39.22%	11 Years
PFE Pfizer	$1.72	6.95%	N/A	91.49%	16 Years

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
BEAM Beam Therapeutics	N/A	6.75	6.75
BLUE bluebird bio	0.37	0.51	0.33
CRSP CRISPR Therapeutics	N/A	16.61	16.61
LLY Eli Lilly and Company	1.86	1.28	1.00
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
BEAM Beam Therapeutics	99.68%
BLUE bluebird bio	87.43%
CRSP CRISPR Therapeutics	69.20%
LLY Eli Lilly and Company	82.53%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.80%
BEAM Beam Therapeutics	3.50%
BLUE bluebird bio	1.40%
CRSP CRISPR Therapeutics	4.10%
LLY Eli Lilly and Company	0.14%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	117.70 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

BEAM, LLY, CRSP, PFE, APLS, and BLUE Headlines

Recent News About These Companies

Pfizer's Golden Cross Signals Strength: How to Play the Stock

1 hour ago | zacks.com

Trump tells drugmakers to 'justify the success' of Covid meds after FDA limits vaccine approval

4 hours ago | cnbc.com

Armistice Capital LLC Acquires Shares of 211,740 Pfizer Inc. $PFE

September 1 at 8:33 AM | marketbeat.com

Baird Financial Group Inc. Sells 188,043 Shares of Pfizer Inc. $PFE

September 1 at 6:41 AM | marketbeat.com

Pfizer's 7% Dividend: Income Gem or Value Trap?

September 1 at 6:30 AM | fool.com

Pfizer's 7% Dividend: Income Gem or Value Trap?

September 1 at 6:00 AM | fool.com

Healthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse

...

August 31 at 10:09 PM | marketbeat.com

FRG Family Wealth Advisors LLC Reduces Stake in Pfizer Inc. $PFE

August 31 at 7:36 AM | marketbeat.com

Centric Wealth Management Acquires 20,164 Shares of Pfizer Inc. $PFE

August 31 at 7:13 AM | marketbeat.com

3 No-Brainer Stocks to Buy Right Now

August 31 at 6:45 AM | fool.com

Magnetar Financial LLC Acquires New Position in Pfizer Inc. $PFE

August 31 at 5:57 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by The Manufacturers Life Insurance Company

August 31 at 5:44 AM | marketbeat.com

Canada Pension Plan Investment Board Sells 2,484,464 Shares of Pfizer Inc. $PFE

August 31 at 5:36 AM | marketbeat.com

Landscape Capital Management L.L.C. Purchases 11,469 Shares of Pfizer Inc. $PFE

August 31 at 5:18 AM | marketbeat.com

Pfizer (PFE) Announces FDA Approval of sBLA for Pfizer-BioNTech COVID-19 Vaccine

August 31 at 2:17 AM | ca.finance.yahoo.com

4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer

August 30 at 9:11 AM | fool.com

4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer

August 30 at 8:45 AM | fool.com

Evergreen Capital Management LLC Has $10.58 Million Holdings in Pfizer Inc. $PFE

August 30 at 7:25 AM | marketbeat.com

Pfizer Inc. $PFE Shares Bought by Te Ahumairangi Investment Management Ltd

August 30 at 6:41 AM | marketbeat.com

Better High-Yielding Dividend Stock: Realty Income vs. Pfizer

August 30 at 6:11 AM | fool.com

Itau Unibanco Holding S.A. Decreases Stake in Pfizer Inc. $PFE

August 30 at 6:00 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BEAM, LLY, CRSP, PFE, APLS, and BLUE Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.57 -0.48 (-1.71%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$27.57 +0.00 (+0.00%)

As of 08/29/2025 06:08 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$16.36 -0.49 (-2.91%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$16.56 +0.20 (+1.22%)

As of 08/29/2025 07:58 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

bluebird bio NASDAQ:BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$51.83 -1.22 (-2.30%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$51.80 -0.03 (-0.06%)

As of 08/29/2025 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Eli Lilly and Company NYSE:LLY

$732.41 +0.45 (+0.06%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$731.25 -1.16 (-0.16%)

As of 08/29/2025 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer NYSE:PFE

$24.74 +0.14 (+0.57%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$24.78 +0.04 (+0.15%)

As of 08/29/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Earnings

Compare Dividends

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BEAM, LLY, CRSP, PFE, APLS, and BLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BEAM, LLY, CRSP, PFE, APLS, and BLUE Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

Beam Therapeutics NASDAQ:BEAM

bluebird bio NASDAQ:BLUE

CRISPR Therapeutics NASDAQ:CRSP

Eli Lilly and Company NYSE:LLY

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools